03:02 , Jun 30, 2018 |  BioCentury  |  Finance

Smitten by SMID-caps

Risk is pervasive heading into the third quarter and choppy waters are expected, but 13 buysiders told BioCentury they’re not afraid to stay the course. A politically charged environment is likely to intensify as the midterm...
05:29 , Jun 2, 2018 |  BioCentury  |  Strategy

Partnering on a mission

With a $260 million war chest and a banner roster of execs, advisors and deals, Brii Biosciences is pushing an agenda to bring infectious diseases to the forefront of innovation in China. Its top priority...
18:38 , May 11, 2018 |  BC Week In Review  |  Company News

Vir acquires antiviral gene-editing biotech Agenovir

Antiviral company Agenovir Corp. is now part of Vir Biotechnology Inc. (San Francisco, Calif.) under a "recent acquisition", according to a Vir spokesperson. Terms of the deal were unavailable through the Vir spokesperson. Agenovir has developed...
21:20 , May 9, 2018 |  BC Extra  |  Company News

Vir acquires antiviral gene-editing biotech Agenovir

Antiviral company Agenovir Corp. is now part of Vir Biotechnology Inc. (San Francisco, Calif.) under a "recent acquisition", according to a Vir spokesperson. Terms of the deal were unavailable through the Vir spokesperson. Agenovir has developed...
19:52 , Feb 23, 2018 |  BioCentury  |  Emerging Company Profile

Cutting viruses

Armed with a suite of CRISPR nucleases and multiple guide RNAs, Excision BioTherapeutics Inc. is using gene editing to cut out integrated latent viruses from host genomes. The newco is starting with HIV, but has...
19:26 , Aug 11, 2017 |  BioCentury  |  Finance

Quake-starting Karius

The former management team and seed investor behind sequencing company Moleculo Inc. have reunited at Karius Inc., and plan to use a new untranched $50 million series A round to launch Karius' infectious disease diagnostic...
22:48 , Jan 13, 2017 |  BioCentury  |  Emerging Company Profile

Seeking viral strongholds

Agenovir Corp. is using CRISPR-based gene editing to eliminate latent viruses. Its lead program will test in vivo delivery of CRISPR-Cas9 components to treat persistent human papillomavirus infection. Viruses that remain dormant within cells for years...
07:00 , Sep 1, 2016 |  BC Extra  |  Company News

Management tracks

Digital health company Adherium Ltd. (ASX:ADR) named Thomas Lynch chairman and said board member Doug Wilson will step down and transition to a part-time role as executive medical director. Lynch also is chairman of Evofem...
00:31 , May 18, 2016 |  BC Extra  |  Financial News

Antiviral company Agenovir raises $10.6M

Agenovir Corp. (South San Francisco, Calif.) raised $10.6 million in a series A round led by VC firm Data Collective. Celgene Corp. (NASDAQ:CELG), Lightspeed Venture Partners and individual investors also participated. The company is developing...